文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

难治性胃食管反流病:管理更新

Refractory Gastroesophageal Reflux Disease: A Management Update.

作者信息

Rettura Francesco, Bronzini Francesco, Campigotto Michele, Lambiase Christian, Pancetti Andrea, Berti Ginevra, Marchi Santino, de Bortoli Nicola, Zerbib Frank, Savarino Edoardo, Bellini Massimo

机构信息

Division of Gastroenterology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

出版信息

Front Med (Lausanne). 2021 Nov 1;8:765061. doi: 10.3389/fmed.2021.765061. eCollection 2021.


DOI:10.3389/fmed.2021.765061
PMID:34790683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8591082/
Abstract

Gastroesophageal reflux disease (GERD) is one of the most frequent gastrointestinal disorders. Proton pump inhibitors (PPIs) are effective in healing lesions and improving symptoms in most cases, although up to 40% of GERD patients do not respond adequately to PPI therapy. Refractory GERD (rGERD) is one of the most challenging problems, given its impact on the quality of life and consumption of health care resources. The definition of rGERD is a controversial topic as it has not been unequivocally established. Indeed, some patients unresponsive to PPIs who experience symptoms potentially related to GERD may not have GERD; in this case the definition could be replaced with "reflux-like PPI-refractory symptoms." Patients with persistent reflux-like symptoms should undergo a diagnostic workup aimed at finding objective evidence of GERD through endoscopic and pH-impedance investigations. The management strategies regarding rGERD, apart from a careful check of patient's compliance with PPIs, a possible change in the timing of their administration and the choice of a PPI with a different metabolic pathway, include other pharmacologic treatments. These include histamine-2 receptor antagonists (H2RAs), alginates, antacids and mucosal protective agents, potassium competitive acid blockers (PCABs), prokinetics, gamma aminobutyric acid-B (GABA-B) receptor agonists and metabotropic glutamate receptor-5 (mGluR5) antagonists, and pain modulators. If there is no benefit from medical therapy, but there is objective evidence of GERD, invasive antireflux options should be evaluated after having carefully explained the risks and benefits to the patient. The most widely performed invasive antireflux option remains laparoscopic antireflux surgery (LARS), even if other, less invasive, interventions have been suggested in the last few decades, including endoscopic transoral incisionless fundoplication (TIF), magnetic sphincter augmentation (LINX) or radiofrequency therapy (Stretta). Due to the different mechanisms underlying rGERD, the most effective strategy can vary, and it should be tailored to each patient. The aim of this paper is to review the different management options available to successfully deal with rGERD.

摘要

胃食管反流病(GERD)是最常见的胃肠道疾病之一。质子泵抑制剂(PPIs)在大多数情况下能有效愈合病变并改善症状,尽管高达40%的GERD患者对PPI治疗反应不佳。难治性胃食管反流病(rGERD)是最具挑战性的问题之一,因为它会影响生活质量并消耗医疗资源。rGERD的定义是一个有争议的话题,因为尚未明确确立。实际上,一些对PPIs无反应但出现可能与GERD相关症状的患者可能并没有GERD;在这种情况下,定义可替换为“类似反流的PPI难治性症状”。持续出现类似反流症状的患者应接受诊断性检查,旨在通过内镜和pH阻抗检查找到GERD的客观证据。rGERD的管理策略,除了仔细检查患者对PPIs的依从性、可能改变给药时间以及选择具有不同代谢途径的PPI外,还包括其他药物治疗。这些药物包括组胺-2受体拮抗剂(H2RAs)、藻酸盐、抗酸剂和黏膜保护剂、钾竞争性酸阻滞剂(PCABs)、促动力药、γ-氨基丁酸-B(GABA-B)受体激动剂和代谢型谷氨酸受体-5(mGluR5)拮抗剂以及疼痛调节剂。如果药物治疗无效,但有GERD的客观证据,则应在向患者仔细解释风险和益处后评估侵入性抗反流方案。即使在过去几十年中有人提出了其他侵入性较小的干预措施,包括内镜经口无切口胃底折叠术(TIF)、磁括约肌增强术(LINX)或射频治疗(Stretta),最广泛实施的侵入性抗反流方案仍然是腹腔镜抗反流手术(LARS)。由于rGERD的潜在机制不同,最有效的策略可能会有所不同,应针对每个患者进行量身定制。本文的目的是综述成功处理rGERD的不同管理方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0361/8591082/27348db57440/fmed-08-765061-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0361/8591082/58fc6e873e04/fmed-08-765061-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0361/8591082/27348db57440/fmed-08-765061-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0361/8591082/58fc6e873e04/fmed-08-765061-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0361/8591082/27348db57440/fmed-08-765061-g0002.jpg

相似文献

[1]
Refractory Gastroesophageal Reflux Disease: A Management Update.

Front Med (Lausanne). 2021-11-1

[2]
AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.

Clin Gastroenterol Hepatol. 2022-5

[3]
Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.

Clin Exp Gastroenterol. 2018-3-21

[4]
Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy.

Gastroenterol Hepatol (N Y). 2014-9

[5]
Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.

Am J Gastroenterol. 2015-4

[6]
Update on Endoscopic Approaches for the Management of Gastroesophageal Reflux Disease.

Gastroenterol Hepatol (N Y). 2019-7

[7]
Transoral incisionless fundoplication with or without hiatal hernia repair for gastroesophageal reflux disease after peroral endoscopic myotomy.

Endosc Int Open. 2024-1-5

[8]
Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.

Dis Esophagus. 2017-2-1

[9]
Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis.

Gastroenterology. 2018-1-3

[10]
Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Dig Dis Sci. 2017-12

引用本文的文献

[1]
MRI-negative cerebellar syndrome caused by medication-induced magnesium deficiency: a case report.

BMC Neurol. 2025-9-9

[2]
Navigating gastrointestinal challenges in genetic myopathies: Diagnostic insights and future directions.

World J Methodol. 2025-12-20

[3]
Five-year clinical outcomes of RefluxStop surgery in the treatment of acid reflux: a prospective multicenter trial of safety and effectiveness.

Surg Endosc. 2025-7-22

[4]
Comparing Proton Pump Inhibitors and Emerging Acid-Suppressive Therapies in Gastroesophageal Reflux Disease: A Systematic Review.

Cureus. 2025-5-17

[5]
Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD.

Therap Adv Gastroenterol. 2025-6-11

[6]
The positive role of Chinese herbal medicine as an adjunctive therapy for refractory gastroesophageal reflux disease: A systematic review and network meta-analysis.

Medicine (Baltimore). 2025-5-23

[7]
Natural Products in the Management of Gastroesophageal Reflux Disease: Mechanisms, Efficacy, and Future Directions.

Nutrients. 2025-3-19

[8]
[Treatment status and progress of laryngopharyngeal reflux disease].

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025-5

[9]
Functional dyspepsia and gastroparesis: are they distinct disorders, a spectrum of diseases or one disease?

eGastroenterology. 2025-1-23

[10]
A retrospective study assessing RefluxStop surgery for gastroesophageal reflux disease: Clinical outcomes in 79 patients from Germany.

Surg Open Sci. 2024-12-18

本文引用的文献

[1]
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis.

Dig Liver Dis. 2021-12

[2]
Low FODMAPs diet or usual dietary advice for the treatment of refractory gastroesophageal reflux disease: An open-labeled randomized trial.

Neurogastroenterol Motil. 2021-9

[3]
Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art.

Drug Des Devel Ther. 2021

[4]
Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.

Biomed Rep. 2021-3

[5]
Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0.

Neurogastroenterol Motil. 2021-1

[6]
ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease.

Neurogastroenterol Motil. 2021-4

[7]
Editorial: acid suppression with potassium-competitive acid blockers dismissing genotype concerns.

Aliment Pharmacol Ther. 2021-1

[8]
European Society for Neurogastroenterology and Motility (ESNM) recommendations for the use of high-resolution manometry of the esophagus.

Neurogastroenterol Motil. 2021-5

[9]
Hypercontractile Esophagus From Pathophysiology to Management: Proceedings of the Pisa Symposium.

Am J Gastroenterol. 2021-2-1

[10]
Postreflux swallow-induced peristaltic wave index from pH-impedance monitoring associates with esophageal body motility and esophageal acid burden.

Neurogastroenterol Motil. 2021-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索